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OBJECTIVES The aim of this study was to determine long-term survival (.10 years) after cardiac
transplantation in the cyclosporine era and identify risk factors influencing long-term survival.
BACKGROUND Despite the availability of newer modalities for heart failure, cardiac transplantation remains
the treatment of choice for end-stage heart disease.
METHODS Between 1983 and 1988, 195 patients underwent heart transplantation at a single center for
the treatment of end-stage heart disease. Multivariable logistic regression analysis of
pretransplant risk factors affecting long-term survival after cardiac transplantation included
various recipient and donor demographic, immunologic and peritransplant variables.
RESULTS Among the group of 195 cardiac transplant recipients, actuarial survival was 72%, 58% and
39% at 1, 5 and 10 years respectively. In the 65 patients who survived .10 years, mean cardiac
index was 2.9 l/m2 and mean ejection fraction was 58%. Transplant-related coronary artery
disease (TRCAD) was detected in only 14 of the 65 patients (22%). By multivariable analysis,
the only risk factor found to adversely affect long-term survival was a pretransplant diagnosis
of ischemic cardiomyopathy (p 5 0.04).
CONCLUSIONS Long-term survivors maintain normal hemodynamic function of their allografts with a low
prevalence of TRCAD. It is possible that similar risk factors that lead to coronary artery
disease in native vessels continue to operate in the post-transplant period, thereby contrib-
uting to adverse outcomes after cardiac transplantation. Aggressive preventive and therapeutic
measures are essential to limit the risk factors for development of coronary atherosclerosis and
enable long-term survival after cardiac transplantation. (J Am Coll Cardiol 2001;37:189–94)
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Cardiac transplantation is the only therapeutic modality to
achieve long-term survival in the treatment of end-stage
heart disease (1,2). The feasibility of long-term survival is an
important consideration, especially with the development of
newer modalities of treatment for end-stage heart disease.
The use of cyclosporine as part of the post-transplant
immunosuppressive regime beginning in the early 1980s has
significantly improved survival in heart transplant recipients
(3,4). However, despite a growing insight into the patho-
genesis of transplant-related coronary artery disease
(TRCAD) in cardiac allograft recipients, it remains the
major cause of late graft failure and death in cardiac
transplant recipients (5). Thus, prevention of TRCAD
remains essential to long-term survival after cardiac trans-
plantation.
The opportunity to study graft function and survival in
the second decade following cardiac transplantation has
been limited to a few centers that were actively performing
cardiac transplantation in the 1980s. This study aims to: 1)
determine the long-term (.10 years) survival of patients
after cardiac transplantation in the cyclosporine era, 2)
evaluate the hemodynamic and functional parameters of
cardiac allograft function in these long-term survivors and
3) identify risk factors adversely affecting long-term survival
after cardiac transplantation.
METHODS
Patient selection. Between April 1, 1983, and June 1988,
195 consecutive patients underwent orthotopic cardiac
transplantation at the Columbia Presbyterian Medical Cen-
ter for the treatment of end-stage heart disease. Selection of
recipients was based on ABO compatibility and donor-
recipient size matching. The reasons for choosing this
period were twofold: 1) cyclosporine was introduced in 1983
and 2) patients transplanted during this era had a potential
to survive .10 years (long-term survival after heart trans-
plantation was the focus of this study).
Operative techniques. Donor hearts were harvested from
beating-heart brain-dead individuals. Graft procurement
was performed either locally or distantly and preservation
was done with cold cardioplegic arrest using Euro-Collin’s
solution and topical hypothermia. Orthotopic cardiac trans-
plantation was performed with the biatrial technique
described by Lower and Shumway (6).
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Immunosuppressive regimen. Since 1983 all patients un-
dergoing cardiac transplantation at the Columbia Presbyte-
rian Medical Center have received cyclosporine-based
immunosuppression. Between April 1, 1983, and April 3,
1985, patients received cyclosporine and steroid therapy
(n 5 35). After April 3, 1985, triple therapy has been
administered to all patients with the addition of azathio-
prine to the immunosuppressive regimen (n 5 135). Intra-
venous murine monoclonal antibody OKT3 (5 mg/day) has
been used instead of cyclosporine for the first four days after
transplantation for patients who have severe renal dysfunc-
tion. Current dosing for standard triple-therapy immuno-
suppression consists of: 1) Cyclosporine is administered in a
preoperative dose of 3 to 6 mg/kg followed by intravenous
cyclosporine (1 to 2 mg/kg/24 h) until oral intake is
tolerated. Daily oral doses (3 to 6 mg/kg) are adjusted so
that serum levels are maintained at 300 to 350 mg/dl. 2)
Azathioprine is administered in a preoperative oral dose
(4 mg/kg) followed by daily doses of 2 mg/kg with dosing
adjusted according to the patient’s white blood cell count,
platelet count and hepatic function. 3) Intravenous methyl-
prednisolone (500 mg) is administered during the operation
and followed in the postoperative period by 125 mg every
8 h for three doses. Prednisone is then instituted at a daily
oral dose of 1 mg/kg and gradually tapered over four months
to 0.1 mg/kg per day.
Management of rejection. Rejection was diagnosed by
routine endomyocardial biopsy, weekly for the first six
weeks, then every two weeks for the next six months and
then once monthly for the next one year. Routine treatment
of rejection consisted of an increase in oral prednisone to
100 mg/day for three days followed by a taper for one week
to the baseline dose. If rejection persisted, as seen on
endomyocardial biopsy, after a course of oral prednisone
therapy, or if rejection was accompanied by altered hemo-
dynamics, intravenous methylprednisolone (1 g daily for
three days) was used to reverse rejection. Intravenous OKT3
(5 mg/day) and antithymocyte globulin were used in hemo-
dynamically unstable patients and in patients with rejection
episodes refractory to intravenous steroid boost. Persistent
rejection episodes post-transplant associated with hemody-
namic instability, despite all attempted measures, were
considered as an indication for retransplantation.
Angiography/diagnosis of coronary disease. All patients
underwent annual coronary angiography. The diagnosis of
TRCAD was based on the following: 1) discrete lesions
resulting in .50% obstruction of the proximal or mid-
portions of major graft vessels or 2) diffuse, concentric
narrowing of the whole vessels, including their branches. If
TRCAD was identified, the frequency of angiography was
increased to a biannual regimen. Patients were not given
routine vasodilators before coronary injections. All angio-
grams were reviewed by a cardiologist and compared with
the previous year’s films to detect the presence of luminal
irregularities, discrete stenoses, loss of third-order branches
or pruning of vessels. Explanted hearts and autopsy speci-
mens were examined for evidence of vessel occlusion and
irregularities, ischemic damage and presence of acute cardiac
rejection.
HLA typing. Serological typing of HLA-A and HLA-B
loci was performed by standard microcytotoxicity tech-
niques. HLA-DR typing was performed by serologic analysis.
Statistical analysis. Data were examined univariately by
the Student t test for continuous variables and Fisher’s exact
test for discrete data. Actuarial survival of patients was
estimated by Kaplan-Meier analysis, with p values calcu-
lated by log-rank statistics (7). For the multivariable survival
analysis post-transplantation, variables with a univariate p
value ,0.25 were entered into a multiple logistic regression
analysis model (8). This model is a multiple regression
analysis for examining dichotomous outcomes and their
potential associated risk factors by modeling a linearized
function of a set of covariates. The interpretation of a risk
factor allowed into the final model with a p value ,0.05 is
that it is an independent risk factor associated with the
event, over and above other potential risk factors included in
the equation. The risk ratio is the ratio of the estimated
hazard for those with the characteristic variable in question
to the estimated hazard for those without, controlling for
other variables (or covariates).
For all statistical analysis, data was analyzed using SAS
System software (SAS Institute, Inc., Cary, North Carolina).
RESULTS
Demographic data. The causes of end-stage heart disease
in this population of 195 patients consisted of ischemic
cardiomyopathy (n 5 67), idiopathic cardiomyopathy (n 5
97), congenital heart disease (n 5 12) and others (n 5 9).
The mean age of patients at transplantation was 38.05 6
15.98 years (range 10 to 64 years). There were 158 male and
37 female patients (male to female ratio 4.3:1).
The mean follow-up period was 6.45 1 5.04 years, with
a cumulative patient follow up time of 1,257 patient years.
A comparison of the demographic features between the
long-term survival group and the non-long-term survival
group is shown in Table 1.
Actuarial survival. The actuarial survival of the 195 pa-
tients undergoing cardiac transplantation between 1983 and
1988 was 72%, 58% and 39% at one, five and ten years
respectively by Kaplan-Meier analysis (Fig. 1). No differ-
ences in one-, five- and ten-year actuarial survival were
found among patients who received triple immunosuppres-
sion (n 5 159) compared with those on dual therapy (n 5
36) (p 5 0.9, Table 2). By comparison, one- and five-year
actuarial survival increased to 81% and 70%, respectively, at
our institution a decade later (1993 to 1997).
Abbreviations and Acronyms
TRCAD 5 transplant-related coronary artery disease
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Graft function in long-term survivors. In patients with
actuarial survival .10 years, 65 cardiac allografts main-
tained function beyond 10 years. Freedom from TRCAD in
these allografts was 98% and 78% at 5 and 10 years
respectively. Hemodynamic evaluation of the cardiac allo-
graft function in long-term survivors revealed a mean
cardiac index of 2.9 l/m2 and a mean ejection fraction of
58% (Table 3).
Univariate and multivariable analysis. Univariate analysis
revealed recipient age at transplant and underlying ischemic
cardiomyopathy as statistically significant risk factors ad-
versely affecting long-term survival after cardiac transplan-
tation. Two other risk factors showed a trend toward
significance: donor age at transplantation and donor is-
chemic time (Table 2). Other variables were not statistically
significant. However, multivariable analysis by logistic re-
gression analysis identified only an initial pretransplant
diagnosis of ischemic cardiomyopathy (p 5 0.04) as a
statistically significant risk factor to adversely affect long-
term survival following cardiac transplantation (Table 4).
Among cardiac allograft recipients with a pretransplant
diagnosis of ischemic cardiomyopathy, only 27% survived
.10 years compared with 43% of those with other pretrans-
plant diagnoses (p , 0.05).
Figure 1. Actuarial survival of patients undergoing primary cardiac transplantation between 1983 and 1988. The squares represent actual events, positioned
along the horizontal axis by the time of the event and by the Kaplan-Meier method along the vertical axis.
Table 1. Distribution of the Demographic Features Between Long-Term and Non-Long-Term
Survivors After Cardiac Transplantation
>10 Years
(n 5 65)
<10 Years
(n 5 106) p Value
1. Age (years) 34.8 6 15 40.3 6 16.5 0.03
2. Gender (male) 53 (81.5%) 86 (81.1%) 0.9
3. Race (Caucasian) 55 (84.6%) 88 (83.0%) 0.7
4. Primary diagnosis
Ischemic cardiomyopathy 15 40 0.04
Idiopathic cardiomyopathy 42 49 0.6
Congenital heart disease 3 9 0.5
5. Ischemic time (min) 146.6 6 43.3 162.02 6 56.3 0.07
6. Postoperative survival (years) 11.7 6 1.3 2.8 6 3.2 —
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DISCUSSION
Several improvements in the discipline of cardiac transplan-
tation have allowed increasing survival in patients with
end-stage heart disease. Cardiac transplantation remains the
proven therapeutic modality to achieve long-term survival in
these patients, despite the development of new surgical
techniques for the treatment of end-stage heart failure such
as partial left ventriculectomy, improved mechanical assist
devices and further progress in the understanding of the
immunological mechanisms in xenotransplantation (9–11).
Survival and quality of life in these patients have steadily
improved as a result of advancement in various fields, but
the development of TRCAD continues to be an impedi-
ment to long-term survival. This study retrospectively eval-
uates a relatively earlier period in our large experience with
cardiac transplantation. Given several changes and advances
made in the treatment of patients with end-stage heart
disease awaiting cardiac transplantation, several lessons can
be learned from past experiences. The feasibility of long-
term survival after cardiac transplantation with satisfactory
hemodynamic function of the cardiac allografts over this
duration is a major justification for the procedure’s contin-
ued use and applicability.
This study shows that long-term survivors of cardiac
transplantation maintain good cardiovascular hemodynamic
function in the absence of TRCAD. Notably, the five-year
incidence of TRCAD in these long-term survivors is sig-
nificantly lower than that reported in the overall transplant
population. Therefore, it appears that prevention of
TRCAD is central in allowing long-term survival and good
hemodynamic function. This result is in agreement with
other studies of long-term survivors where hemodynamic
parameters determined at five years after cardiac transplan-
tation were normal. DeCampli et al. (12) from Stanford
reported on a group of long-term survivors with adequate
graft function in the second decade after heart transplanta-
tion. In a group of 71 patients followed up to seven years
after cardiac transplantation, no evidence was found of
systolic dysfunction or dilated or restrictive cardiomyopathy
(13). Similarly, no evidence of impairment of graft hemo-
dynamic function was reported in 174 patients followed for
a period of 5 years (14).
Several nonimmunological and immunological risk
factors have been implicated in the development of
TRCAD after cardiac transplantation (15). Traditional risk
factors for atherosclerosis such as hypertension, smoking
and elevated plasma triglycerides have also been described as
predisposing factors for TRCAD. Similar to earlier studies,
our study demonstrated that the principal risk factor for
poor survival due to TRCAD is a pretransplant diagnoses of
ischemic heart disease (16). This further emphasizes the
need to monitor and prevent the known risk factors for
atherosclerosis in the post-transplant period. These risk
factors and consequently the incidence of TRCAD may be
reduced by the use of lipid-lowering agents and calcium
channel blockers (17–19). Additional risk factors for
TRCAD include prolonged ischemic time and older donor
age (20). These were also identified as risk factors in our
study population.
The relationship between prolonged ischemic time and
TRCAD may reflect release of endothelial-derived factors
such as nitric oxide and endothelin, which are known to
exert significant negative influence on myocardial function
(21). In addition, damaged endothelium may be a better
target for immune attack. The possibility of allograft endo-
thelial dysfunction contributing to TRCAD gained impetus
from the recognition that endothelial dysfunction is linked
to the development of atherosclerosis in nontransplanted
individuals. Donor hearts from older individuals may be at
Table 2. Univariate Analysis of Factors Affecting Long-Term
Survival After Cardiac Transplantation
Risk Factor p Value
Demographic variables
Recipient age at transplantation 0.03
Recipient gender 0.9
Recipient race 0.8
Donor age at transplantation 0.07
Donor gender 0.8
Donor race 0.8
Indications for surgery
Ischemic cardiomyopathy 0.04
Idiopathic cardiomyopathy 0.6
Immunological variables
HLA A matching 0.7
HLA B matching 0.2
HLA DR matching 0.2
Panel reactive antibody (PRA) 0.3
Perioperative factors
Donor ischemic time 0.07
Prior cardiac surgery 0.2
OKT3 induction therapy 0.9
Type of immunosuppression
(triple vs. double therapy) 0.9
Table 3. Hemodynamic Parameters in Long-Term Survivors at
10-Year Follow-Up
Hemodynamic
Parameter Mean 6 SD
CO (l/min) 3.4 6 1.5
CI (l/min/m2) 2.9 6 0.9
PCW (mm Hg) 8.2 6 5.1
PVRI (dyne/s/m2) 109 6 49
SVRI (dyne/s/m2) 1691 6 490
EF (%) 58 6 10
CO 5 cardiac output; CI 5 cardiac index; EF 5 ejection fraction; PCW 5
pulmonary capillary wedge; PVRI 5 pulmonary vascular resistance index; SVRI 5
systemic vascular resistance index.
Table 4. Multivariate Analysis of Factors Affecting Long-Term
Survival After Cardiac Transplantation
Risk Factor p Value
Risk
Ratio 95% CI Coefficient
Ischemic cardiomyopathy 0.04 2.02 1.01, 4.06 0.7032
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increased risk for myocardial dysfunction as well as for the
earlier development of TRCAD because of underlying athero-
sclerosis. Immunological risk factors that have been implicated
include elevated pretransplant panel reactive antibody level,
number of episodes of acute rejection, HLA mismatches,
steroid dosage and CMV infection (22–24). Thus, it is likely
that a combination of immunological and nonimmunological
factors contribute to the development of TRCAD.
Transplant-related coronary artery disease may be related to
the recipient’s continuing immune response against donor
major-histocompatibility complex antigens, because long-term
allograft survival correlated directly with the number of donor-
recipient HLA matches and inversely with the development of
circulating antibodies against donor HLA-DR molecules
(25,26). Because donor-recipient HLA-DR mismatching is
associated with increased cardiac allograft rejection episodes,
TRCAD may be the end result of recurrent or persistent
allograft rejection (27–29).
Study limitations. The limitations of this study include
those related to a retrospectively performed study. There is
also a possibility of underreporting of TRCAD, especially
with the recent use of intravascular ultrasound that has
improved the detection of TRCAD. Moreover, identifica-
tion of risk factors for the development of TRCAD was
beyond the scope of this study. Many of the short-term
survivors died within one year and many did not have autopsy
studies. Thus, any data commenting on the prevalence of
TRCAD in non-long-term survivors would be erroneously
applied to this population. Further, several advances in the field
of cardiac transplantation have significantly changed the overall
management of these patients from that in use a decade ago
(30). Despite these disadvantages, the ability to study a cohort
of patients from a previous decade provides a unique opportu-
nity to study the influence of several variables on long-term
survival after cardiac transplantation.
Conclusions. Long-term survival with normally function-
ing cardiac allografts well into the second decade after heart
transplantation is feasible in a subset of patients with
end-stage heart disease. The major obstacle for achieving
this status in more patients appears to be the risk for the
recurrence of ischemic cardiomyopathy due to atherosclero-
sis and TRCAD. These results are even more encouraging
when considering the tremendous advances that have oc-
curred in the past several years in the prevention and
management of both immunologic and nonimmunologic
risk factors for TRCAD. Strict attention to the avoidance of
known risk factors for CAD, as well as increased use of lipid
lowering and anti-hypertensive agents in the post-transplant
period for patients receiving cardiac allografts, is essential to
allow long-term survival in these patients.
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